{"id":"https://openalex.org/W2919781000","doi":"https://doi.org/10.1002/pbc.27682","title":"Cutaneous reactions to targeted therapies in children with CNS tumors: A cross\u2010sectional study","display_name":"Cutaneous reactions to targeted therapies in children with CNS tumors: A cross\u2010sectional study","publication_year":2019,"publication_date":"2019-02-28","ids":{"openalex":"https://openalex.org/W2919781000","doi":"https://doi.org/10.1002/pbc.27682","mag":"2919781000","pmid":"https://pubmed.ncbi.nlm.nih.gov/30821092"},"language":"en","primary_location":{"id":"doi:10.1002/pbc.27682","doi":"https://doi.org/10.1002/pbc.27682","is_oa":false,"landing_page_url":"https://doi.org/10.1002/pbc.27682","pdf_url":null,"source":{"id":"https://openalex.org/S119714264","display_name":"Pediatric Blood & Cancer","issn_l":"1545-5009","issn":["1545-5009","1545-5017"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pediatric Blood & Cancer","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5049661758","display_name":"Hannah Song","orcid":"https://orcid.org/0000-0002-9999-4943","observed_orcids":["https://orcid.org/0000-0002-9999-4943"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hannah Song","raw_affiliation_strings":["Department of Pediatrics Massachusetts General Hospital Massachusetts Boston"],"raw_orcid":"https://orcid.org/0000-0002-9999-4943","affiliations":[{"raw_affiliation_string":"Department of Pediatrics Massachusetts General Hospital Massachusetts Boston","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065520106","display_name":"Connie S. Zhong","orcid":"https://orcid.org/0000-0003-1222-360X","observed_orcids":["https://orcid.org/0000-0003-1222-360X"]},"institutions":[{"id":"https://openalex.org/I1288882113","display_name":"Boston Children's Hospital","ror":"https://ror.org/00dvg7y05","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1288882113"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Connie S. Zhong","raw_affiliation_strings":["Dermatology Program Boston Children's Hospital Boston Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dermatology Program Boston Children's Hospital Boston Massachusetts","institution_ids":["https://openalex.org/I1288882113"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060208068","display_name":"Mark W. Kieran","orcid":"https://orcid.org/0000-0003-2184-7692","observed_orcids":["https://orcid.org/0000-0003-2184-7692"]},"institutions":[{"id":"https://openalex.org/I4210166317","display_name":"Dana-Farber/Boston Children's Cancer and Blood Disorders Center","ror":"https://ror.org/05k11pb55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1288882113","https://openalex.org/I4210117453","https://openalex.org/I4210166317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark W. Kieran","raw_affiliation_strings":["Department of Pediatric Oncology Dana-Farber/Boston Children's Cancer Center and Blood Disorder Center Boston Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pediatric Oncology Dana-Farber/Boston Children's Cancer Center and Blood Disorder Center Boston Massachusetts","institution_ids":["https://openalex.org/I4210166317"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068793931","display_name":"Susan N Chi","orcid":"https://orcid.org/0000-0001-7753-878X","observed_orcids":["https://orcid.org/0000-0001-7753-878X"]},"institutions":[{"id":"https://openalex.org/I4210166317","display_name":"Dana-Farber/Boston Children's Cancer and Blood Disorders Center","ror":"https://ror.org/05k11pb55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1288882113","https://openalex.org/I4210117453","https://openalex.org/I4210166317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Susan N. Chi","raw_affiliation_strings":["Department of Pediatric Oncology Dana-Farber/Boston Children's Cancer Center and Blood Disorder Center Boston Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pediatric Oncology Dana-Farber/Boston Children's Cancer Center and Blood Disorder Center Boston Massachusetts","institution_ids":["https://openalex.org/I4210166317"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090423495","display_name":"Karen D. Wright","orcid":"https://orcid.org/0000-0002-9578-1545","observed_orcids":["https://orcid.org/0000-0002-9578-1545"]},"institutions":[{"id":"https://openalex.org/I4210166317","display_name":"Dana-Farber/Boston Children's Cancer and Blood Disorders Center","ror":"https://ror.org/05k11pb55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1288882113","https://openalex.org/I4210117453","https://openalex.org/I4210166317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Karen D. Wright","raw_affiliation_strings":["Department of Pediatric Oncology Dana-Farber/Boston Children's Cancer Center and Blood Disorder Center Boston Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pediatric Oncology Dana-Farber/Boston Children's Cancer Center and Blood Disorder Center Boston Massachusetts","institution_ids":["https://openalex.org/I4210166317"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5003107485","display_name":"Jennifer T. Huang","orcid":"https://orcid.org/0000-0001-6191-7486","observed_orcids":["https://orcid.org/0000-0001-6191-7486"]},"institutions":[{"id":"https://openalex.org/I1288882113","display_name":"Boston Children's Hospital","ror":"https://ror.org/00dvg7y05","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1288882113"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jennifer T. Huang","raw_affiliation_strings":["Dermatology Program Boston Children's Hospital Boston Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dermatology Program Boston Children's Hospital Boston Massachusetts","institution_ids":["https://openalex.org/I1288882113"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5003107485"],"corresponding_institution_ids":["https://openalex.org/I1288882113"],"apc_list":{"value":3550,"currency":"USD","value_usd":3550},"apc_paid":null,"fwci":3.2775,"has_fulltext":false,"cited_by_count":35,"citation_normalized_percentile":{"value":0.91106719,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"66","issue":"6","first_page":"e27682","last_page":"e27682"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12937","display_name":"Chemotherapy-related skin toxicity","score":0.9937000274658203,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12937","display_name":"Chemotherapy-related skin toxicity","score":0.9937000274658203,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11117","display_name":"Drug-Induced Adverse Reactions","score":0.0010999999940395355,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.0010999999940395355,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cutaneous-adverse-effects","display_name":"cutaneous adverse events","score":0.9070000052452087},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.8669999837875366},{"id":"https://openalex.org/keywords/pediatric-cns-tumors","display_name":"pediatric central nervous system tumors","score":0.9319999814033508},{"id":"https://openalex.org/keywords/braf-inhibitors","display_name":"BRAF inhibitors","score":0.9350000023841858},{"id":"https://openalex.org/keywords/mek-inhibitors","display_name":"MEK inhibitors","score":0.9810000061988831},{"id":"https://openalex.org/keywords/mtor-inhibitors","display_name":"mTOR inhibitors","score":0.9879999756813049},{"id":"https://openalex.org/keywords/dabrafenib","display_name":"dabrafenib","score":0.8960000276565552},{"id":"https://openalex.org/keywords/trametinib","display_name":"trametinib","score":0.996999979019165},{"id":"https://openalex.org/keywords/everolimus","display_name":"everolimus","score":1.0},{"id":"https://openalex.org/keywords/dry-skin","display_name":"dry skin","score":0.9850000143051147},{"id":"https://openalex.org/keywords/skin-surveillance","display_name":"skin surveillance","score":0.5090000033378601},{"id":"https://openalex.org/keywords/medication-discontinuation","display_name":"drug discontinuation","score":0.6840000152587891}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.954717218875885},{"id":"https://openalex.org/C2778472372","wikidata":"https://www.wikidata.org/wiki/Q7833138","display_name":"Trametinib","level":4,"score":0.8292382955551147},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.6811460256576538},{"id":"https://openalex.org/C2781249067","wikidata":"https://www.wikidata.org/wiki/Q17142288","display_name":"MEK inhibitor","level":4,"score":0.6729786396026611},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6165122389793396},{"id":"https://openalex.org/C2778830669","wikidata":"https://www.wikidata.org/wiki/Q3011604","display_name":"Dabrafenib","level":5,"score":0.43123936653137207},{"id":"https://openalex.org/C2779699572","wikidata":"https://www.wikidata.org/wiki/Q421052","display_name":"Everolimus","level":2,"score":0.41822510957717896},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.41584303975105286},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.3936174213886261},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3710266947746277},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.3503093719482422},{"id":"https://openalex.org/C57074206","wikidata":"https://www.wikidata.org/wiki/Q14197552","display_name":"MAPK/ERK pathway","level":3,"score":0.3100889325141907},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.1197563111782074},{"id":"https://openalex.org/C2776131300","wikidata":"https://www.wikidata.org/wiki/Q423111","display_name":"Vemurafenib","level":4,"score":0.11810475587844849},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.07690191268920898},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.0},{"id":"https://openalex.org/C2994587330","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Metastatic melanoma","level":3,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D002648","descriptor_name":"Child","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002675","descriptor_name":"Child, Preschool","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003430","descriptor_name":"Cross-Sectional Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003875","descriptor_name":"Drug Eruptions","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005500","descriptor_name":"Follow-Up Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007093","descriptor_name":"Imidazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010091","descriptor_name":"Oximes","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011379","descriptor_name":"Prognosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011728","descriptor_name":"Pyridones","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011744","descriptor_name":"Pyrimidinones","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D012871","descriptor_name":"Skin Diseases","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D016543","descriptor_name":"Central Nervous System Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D016543","descriptor_name":"Central Nervous System Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058990","descriptor_name":"Molecular Targeted Therapy","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1002/pbc.27682","doi":"https://doi.org/10.1002/pbc.27682","is_oa":false,"landing_page_url":"https://doi.org/10.1002/pbc.27682","pdf_url":null,"source":{"id":"https://openalex.org/S119714264","display_name":"Pediatric Blood & Cancer","issn_l":"1545-5009","issn":["1545-5009","1545-5017"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pediatric Blood & Cancer","raw_type":"journal-article"},{"id":"pmid:30821092","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30821092","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pediatric blood & cancer","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":26,"referenced_works":["https://openalex.org/W1490493239","https://openalex.org/W1560814177","https://openalex.org/W1827097565","https://openalex.org/W1917720781","https://openalex.org/W1991185441","https://openalex.org/W1991915991","https://openalex.org/W2013926482","https://openalex.org/W2027654820","https://openalex.org/W2068646871","https://openalex.org/W2107441799","https://openalex.org/W2139311691","https://openalex.org/W2146267855","https://openalex.org/W2154748904","https://openalex.org/W2155461614","https://openalex.org/W2160039867","https://openalex.org/W2166655582","https://openalex.org/W2167255778","https://openalex.org/W2229841771","https://openalex.org/W2345379191","https://openalex.org/W2407635643","https://openalex.org/W2486684008","https://openalex.org/W2518848423","https://openalex.org/W2566164067","https://openalex.org/W2591910005","https://openalex.org/W2763890667","https://openalex.org/W2781938344"],"related_works":["https://openalex.org/W2809596334","https://openalex.org/W3043280112","https://openalex.org/W2763890667","https://openalex.org/W2566164067","https://openalex.org/W4398228956","https://openalex.org/W3115543520","https://openalex.org/W4281759277","https://openalex.org/W4384563150","https://openalex.org/W4281745660","https://openalex.org/W4387014984"],"abstract_inverted_index":{"BACKGROUND:":[0],"MAPK":[1],"(RAS-RAF-MEK-ERK-MAP)":[2],"and":[3,47,70,92,102,134,186,193,220,230,238],"mTOR":[4,48,71,140],"inhibitors":[5,49,192],"are":[6,217],"novel":[7],"treatments":[8],"for":[9,74],"pediatric":[10,30],"central":[11],"nervous":[12],"system":[13],"(CNS)":[14],"tumors.":[15,54],"The":[16,32,176],"literature":[17],"on":[18,190,196],"common":[19,40,178],"cutaneous":[20,41,206],"adverse":[21,42],"reactions":[22,43,179,210],"to":[23,38,44,156,204,211],"these":[24],"therapies":[25],"is":[26],"sparse":[27],"in":[28,50,116,215],"the":[29,99,117],"population.":[31],"aim":[33],"of":[34,65,89,167,236,241],"this":[35,57],"study":[36],"was":[37,146,159],"describe":[39],"BRAF,":[45,68],"MEK,":[46,69],"children":[51,216],"with":[52],"CNS":[53,76],"METHODS:":[55],"In":[56],"cross-sectional":[58],"study,":[59],"patients":[60,113,169,189],"younger":[61],"than":[62],"21":[63],"years":[64,148],"age":[66,143],"receiving":[67],"inhibitor":[72,199],"monotherapy":[73],"a":[75,81,124,131,197],"tumor":[77],"were":[78,96,106,114],"enrolled":[79,115],"over":[80],"one-year":[82],"period.":[83],"Full":[84],"body":[85],"skin":[86,104,157,174],"examination,":[87],"photographs":[88],"dermatologic":[90],"findings,":[91],"initial":[93,100],"treatment":[94,154,181],"recommendations":[95],"included":[97,183],"at":[98,144,171],"visit,":[101],"follow-up":[103],"examinations":[105],"recommended":[107],"every":[108],"three":[109],"months.":[110],"RESULTS:":[111],"Twenty-two":[112],"study.":[118],"Fifty":[119],"percent":[120,165],"(11/22)":[121],"received":[122,129,137],"trametinib,":[123],"MEK":[125,191],"inhibitor,":[126,133],"27.3%":[127],"(6/22)":[128],"dabrafenib,":[130],"BRAF":[132,198],"22.7%":[135],"(5/22)":[136],"everolimus,":[138],"an":[139],"inhibitor.":[141],"Median":[142,151],"visit":[145],"11":[147],"(range,":[149,162],"3-19).":[150],"time":[152],"from":[153],"initiation":[155],"examination":[158],"4.5":[160],"months":[161],"0-43).":[163],"Ninety-six":[164],"(21/22)":[166],"all":[168],"had":[170],"least":[172],"one":[173,194],"reaction.":[175],"most":[177],"across":[180],"groups":[182],"follicular/acneiform":[184],"eruptions":[185],"xerosis.":[187],"Two":[188],"patient":[195],"required":[200],"therapy":[201,214],"cessation":[202],"due":[203],"severe":[205],"reactions.":[207],"CONCLUSIONS:":[208],"Cutaneous":[209],"targeted":[212],"anticancer":[213],"common,":[218],"treatable,":[219],"rarely":[221],"require":[222],"drug":[223],"dose":[224],"reduction":[225],"or":[226],"discontinuation.":[227],"Routine":[228],"surveillance":[229],"early":[231],"intervention":[232],"may":[233],"improve":[234],"quality":[235],"life":[237],"facilitate":[239],"continuation":[240],"life-saving":[242],"therapy.":[243]},"counts_by_year":[{"year":2026,"cited_by_count":9},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":6},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":7},{"year":2019,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2019-03-11T00:00:00"}